Recovery of response to platinum with lonidamine in previously treated metastatic ovarian cancer. Preliminary results

M. De Lena, A. De Mitrio, A. Catino, V. Lorusso, M. Brandi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Fifteen patients with advanced ovarian cancer who progressed or relapsed after initial cisplatinum-based treatment were admitted into a phase II study with oral lonidamine in association with a weekly cisplatin schedule. One complete and four partial clinical responses were observed (5/15:33%). Stable disease and progression were observed in 1 and 9 cases, respectively. The activity demonstrated in refractory or early relapsed patients (14% and 50% objective responses, respectively), together with the good feasibility and tolerability support the clinical use of this regimen, at least as salvage therapy. However, an increased number of patients are needed to better define the role played by lonidamine in the reversal of cisplatin resistance in ovarian cancer and in other tumors.

Original languageEnglish
Pages (from-to)779-782
Number of pages4
JournalInternational Journal of Oncology
Volume4
Issue numberSUPPL.
Publication statusPublished - 1994

Fingerprint

Platinum
Ovarian Neoplasms
Cisplatin
Salvage Therapy
Disease Progression
Appointments and Schedules
lonidamine
Neoplasms
Therapeutics

Keywords

  • advanced ovarian cancer
  • carboplatin
  • cisdiamminedichloroplatinum
  • lonidamine
  • reversal of drug resistance

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Recovery of response to platinum with lonidamine in previously treated metastatic ovarian cancer. Preliminary results. / De Lena, M.; De Mitrio, A.; Catino, A.; Lorusso, V.; Brandi, M.

In: International Journal of Oncology, Vol. 4, No. SUPPL., 1994, p. 779-782.

Research output: Contribution to journalArticle

@article{71f205fc0da14bf79af6557f8d8258f3,
title = "Recovery of response to platinum with lonidamine in previously treated metastatic ovarian cancer. Preliminary results",
abstract = "Fifteen patients with advanced ovarian cancer who progressed or relapsed after initial cisplatinum-based treatment were admitted into a phase II study with oral lonidamine in association with a weekly cisplatin schedule. One complete and four partial clinical responses were observed (5/15:33{\%}). Stable disease and progression were observed in 1 and 9 cases, respectively. The activity demonstrated in refractory or early relapsed patients (14{\%} and 50{\%} objective responses, respectively), together with the good feasibility and tolerability support the clinical use of this regimen, at least as salvage therapy. However, an increased number of patients are needed to better define the role played by lonidamine in the reversal of cisplatin resistance in ovarian cancer and in other tumors.",
keywords = "advanced ovarian cancer, carboplatin, cisdiamminedichloroplatinum, lonidamine, reversal of drug resistance",
author = "{De Lena}, M. and {De Mitrio}, A. and A. Catino and V. Lorusso and M. Brandi",
year = "1994",
language = "English",
volume = "4",
pages = "779--782",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "SUPPL.",

}

TY - JOUR

T1 - Recovery of response to platinum with lonidamine in previously treated metastatic ovarian cancer. Preliminary results

AU - De Lena, M.

AU - De Mitrio, A.

AU - Catino, A.

AU - Lorusso, V.

AU - Brandi, M.

PY - 1994

Y1 - 1994

N2 - Fifteen patients with advanced ovarian cancer who progressed or relapsed after initial cisplatinum-based treatment were admitted into a phase II study with oral lonidamine in association with a weekly cisplatin schedule. One complete and four partial clinical responses were observed (5/15:33%). Stable disease and progression were observed in 1 and 9 cases, respectively. The activity demonstrated in refractory or early relapsed patients (14% and 50% objective responses, respectively), together with the good feasibility and tolerability support the clinical use of this regimen, at least as salvage therapy. However, an increased number of patients are needed to better define the role played by lonidamine in the reversal of cisplatin resistance in ovarian cancer and in other tumors.

AB - Fifteen patients with advanced ovarian cancer who progressed or relapsed after initial cisplatinum-based treatment were admitted into a phase II study with oral lonidamine in association with a weekly cisplatin schedule. One complete and four partial clinical responses were observed (5/15:33%). Stable disease and progression were observed in 1 and 9 cases, respectively. The activity demonstrated in refractory or early relapsed patients (14% and 50% objective responses, respectively), together with the good feasibility and tolerability support the clinical use of this regimen, at least as salvage therapy. However, an increased number of patients are needed to better define the role played by lonidamine in the reversal of cisplatin resistance in ovarian cancer and in other tumors.

KW - advanced ovarian cancer

KW - carboplatin

KW - cisdiamminedichloroplatinum

KW - lonidamine

KW - reversal of drug resistance

UR - http://www.scopus.com/inward/record.url?scp=0028295234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028295234&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 779

EP - 782

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - SUPPL.

ER -